This Is Dividend Stock Johnson & Johnson’s Major Weakness

Although diversification can sometimes be a strength, it can also prove to be a double-edged sword in the long run. Here’s how.

Apr 25, 2014 at 9:30AM

In a previous article on J&J (NYSE:JNJ), I highlighted the company's major strengths -- and it has many, not least of which is its 2.7% dividend yield. Now it's time to focus on its major weakness.

Diversity: A double-edged sword
While J&J's diversity could be seen as a major source of strength for the company, because it provides reduced risk and volatility in the company's sales and profitability, it is not a perfect attribute. By having consumer and medical devices segments in addition to a pharma segment, J&J is less exposed to challenges faced in those divisions; but the company may also miss out on the positive surprises in its segments, too.

Diversification can mean that a company spreads itself too thinly. By this, I mean that it attempts to specialize in a number of areas and business lines; however, it can end up achieving diversification while performing its varied tasks at a sub-optimal level. This can be due to an inefficient allocation of capital. For example, investing too much cash in an underperforming business segment to try and turn it around when the money could be better spent in a different segment that is already highly profitable.

Sector peers
Sector peers, such as Pfizer (NYSE:PFE) and Abbott Laboratories, are attempting to become more specialized than J&J. For instance, pharmaceuticals accounted for 93% of Pfizer's sales in 2013, with the remainder being made up of its consumer health-care segment. Of course, even that specialization still left Pfizer with a revenue decline of 6.5% last year, as compared to J&J's revenue growth of 11%.

While this is only a one-year time period, an increased focus on non-pharma activities does not seem to have hurt J&J in recent years when compared to sector peer Pfizer. However, it raises the question of whether J&J's performance could have been even better were it not for the distraction of less-profitable, but more stable, segments. Indeed, it appears as though Pfizer reached this conclusion and decided to sell off its animal health and nutrition segments in recent years in order to focus time and capital on the most lucrative segment: pharmaceuticals. Could a similar approach from J&J deliver even more profit for shareholders?

Meanwhile, Abbott Laboratories spun-off its research-based pharmaceutical business, AbbVie, on January 1, 2013. In 2013, Abbott Laboratories posted improved sales growth, with the top line increasing by 1.6% compared to 2012. This was higher than the 0.4% sales growth reported in 2012, although clearly the potentially positive effects of the spin-off will take more time to come through. It does, however, show that other companies in the health-care space, such as Abbott Laboratories, are seeking to narrow their specialism in an attempt to stimulate sales and profits.

Looking Ahead
While J&J is currently performing well, as its first quarter update recently showed -- sales up 3.5%, earnings per share up 6.9% versus the first quarter of 2013 -- it could be argued that three separate businesses, as opposed to three segments within the same business, could perform even better, and add even more value for shareholders.

Sure, many investors may argue that a winning formula should not be changed, but if J&J -- or any company -- wants to stay ahead of the competition, it must embrace change and be bold with regard to the changes it makes. Splitting into three distinct entities could maximise profitability, and allow investors in the stock to still access diversification benefits through owning shares in all three entities, while also overcoming what could prove to be J&J's major weakness: spreading itself too thin. 

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.

 

Peter Stephens has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers